An interview with an infectious diseases expert on how respiratory syncytial virus (RSV) impacts populations, current treatments, and best methods for prevention.
Crying baby receives vaccine in the hospital
(Adobe Stock 669414390 by Yuwarin)
Recently, Infection Control Today spoke with Edward Walsh, MD, professor of Medicine, Infectious Diseases, at the University of Rochester Medical Center in New York about RSV, who the disease impacts, available treatments, and how to best manage in health care settings.
What is respiratory syncytial virus (RSV), and what are its common symptoms?
RSV is a very common virus that circulates widely from fall until spring. It causes typical respiratory symptoms of runny nose and cough and can also induce wheezing and shortness of breath. All age groups, from the youngest infants to oldest adults are susceptible. The illness generally lasts from 10 to 30 days.
Can RSV infections lead to long-term health complications in children or adults?
RSV infection in early childhood has been linked to the development of asthma later in childhood and adulthood. In one study, severe RSV in childhood was associated with progression of COPD in adults who smoke.
Are there vaccines available for RSV, and what is their effectiveness?
Currently, there are 2 licensed RSV vaccines, both based on one of the RSV proteins. A vaccine made by GSK is available for adults over age 60, while the vaccine made by Pfizer is available for adults over age 60 and also for pregnant women in order to prevent illness in their newborns by transfer of maternal antibody to the infant at birth. In adults, the vaccines were 85% effective at preventing severe RSV infections. Infants born to mothers vaccinated with the Pfizer vaccine had more than a 60% reduction in RSV infection including medically attended illness.
What are the key differences in RSV symptoms and severity between infants, older children, and adults?
Symptoms in infants, older children, and adults are very similar with the exception that infants are more likely to wheeze. Severity of RSV is greatest in the very young infant, less that 3 months of age, and also in the oldest adults above age 75 and those with certain underlying medical conditions, such as COPD, asthma and heart disease.
Edward Walsh, MD, professor of infectious diseases at the University of Rochester Medical Center
(Photo Credit of University of Rochester Medical Center)
How can health care providers differentiate between RSV and other respiratory illnesses when diagnosing patients?
The only definitive way to differentiate RSV from influenza, SARS-CoV-2 (COVID-19), or other viruses that cause common the cold is to perform a diagnostic test. This is generally done by collecting a nasal swab and testing.
What should individuals do to minimize the risk of RSV infection, especially during RSV season?
The virus is quite prevalent and thus hard to avoid, especially during the holiday season when there is so much person-to-person contact. Nevertheless, avoiding persons with respiratory illness is important, especially close hands-on contact. Of course, for the older adult, the vaccine would reduce illness risk.
How has the COVID-19 pandemic affected the incidence and management of RSV infections?
During the first 18 months of the COVID pandemic, RSV completely disappeared, as did most of the other respiratory viruses, such as influenza. It was thought this was in large part related to social distancing, school closures, and masking. When public activity started to resume, normal RSV illness rose to high levels in July 2021 among children but not in adults. The following year the annual epidemic started in late August and ended by early January. This year, RSV illnesses started in October, and I expect it to return to normal and end in April.
Are there specific recommendations for RSV prevention in health care settings or long-term care facilities?
Yes, any health care worker with a respiratory illness should not care for patients when secretions cannot be controlled. Hand washing and wearing gowns and a mask are also of great help in reducing spread. Identification of infected residents of Long-Term Care Facilities should be attempted, and if RSV is identified, they should be prevented from having contact with other residents until the illness passes.
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.